Ivan Spasojevic

Dr. Ivan Spasojevic

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Clinica Chimica Acta
Verified
Journal Article
Closed access
DIDora Il'Yasova
Dora Il'Yasova
PSPeter Scarbrough
Peter Scarbrough
ISIvan Spasojevic
Ivan Spasojevic

2 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LTLi-Chung Tsao
Li-Chung Tsao
JWJohn S. Wang
John S. Wang
XMXingru Ma
Xingru Ma
SSSirajbir Sodhi
Sirajbir Sodhi
JRJoey V. Ragusa
Joey V. Ragusa
ZHZachary Conrad Hartman
Zachary Conrad Hartman
Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) targeting HER2, exhibiting significant clinical efficacy in breast cancer (BC) with varying HER2 expression, including HER2-low and HER2-ultralow. However, the precise mechanism underlying its efficacy and the contribution of immune activation in these settings remain unclear. Here, we demonstrate that T-DXd efficacy in HER2-low and HER2-negative BC is independent of HER2 engagement and ADC internalization. Instead, its activity relies on extracellular proteases, such as cathepsin L (CTSL), within the tumor microenvironment. Irrespective of their HER2 status, tumor and stromal compartments of invasive BC abundantly express CTSL, which efficiently cleaves the specialized linker of T-DXd, facilitating payload release and inducing cytotoxicity against HER2-low/negative tumors. In HER2-positive BC, the antibody backbone of T-DXd engages Fcγ-receptors and drives antibody-dependent cellular phagocytosis (ADCP). Concurrently, its cytotoxic payload (DXd) induces immunogenic cell death, further activating myeloid cells via TLR4 and STING pathways to enhance tumor antigen presentation to CD8+ T cells. Notably, T-DXd cytotoxicity also upregulates tumor CD47 expression, dampening immune activation. Combining T-DXd with CD47 checkpoint blockade significantly enhances anti-tumor immune responses in a HER2-transgenic BC mouse model, while also inducing durable CD8+ T cell memory to prevent tumor recurrence after therapy cessation.

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Ines Batinic-HaberleInes Batinic-Haberle
Ines Batinic-Haberle
ATArtak Tovmasyan
Artak Tovmasyan
ZHZhiqing Huang
Zhiqing Huang
WDWeina Duan
Weina Duan
LDLi Du
Li Du
ASAngeles Alvarez Secord
Angeles Alvarez Secord
Mn(III) ortho‐N‐alkyl‐ and N‐alkoxyalkyl porphyrins (MnPs) were initially developed as superoxide dismutase (SOD) mimics. These compounds were later shown to react with numerous reactive species (such as ONOO-, H2O2, H2S, CO3•-, ascorbate, and GSH). Moreover, the ability of MnPs to oxidatively modify activities of numerous proteins has emerged as their major mechanism of action both in normal and in cancer cells. Among those proteins are transcription factors (NF‐κB and Nrf2), mitogen‐activated protein kinases, MAPKs, antiapoptotic bcl‐2, and endogenous antioxidative defenses. The lead Mn porphyrins, namely, MnTE‐2‐PyP5+ (BMX‐010, AEOL10113), MnTnBuOE‐2‐PyP5+ (BMX‐001), and MnTnHex‐2‐PyP5+, were tested in numerous injuries of normal tissue and cellular and animal cancer models. The wealth of the data led to the progression of MnTnBuOE‐2‐PyP5+ into four Phase II clinical trials on glioma, head and neck cancer, anal cancer, and multiple brain metastases, while MnTE‐2‐PyP5+ is in Phase II clinical trial on atopic dermatitis and itch.

1 May 2013 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
TWTin Weitner
Tin Weitner
IKIvan Kos
Ivan Kos
HSHuaxin Sheng
Huaxin Sheng
ATArtak Tovmasyan
Artak Tovmasyan
JRJulio Reboucas
Julio Reboucas
ISIvan Spasojevic
Ivan Spasojevic

9 August 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
JZJinshi Zhao
Jinshi Zhao
CCC. Skyler Cochrane
C. Skyler Cochrane
JNJavaria Najeeb
Javaria Najeeb
DGDavid Gooden
David Gooden
CSCarly Sciandra
Carly Sciandra
PZPei Zhou
Pei Zhou
The UDP-3- O -( R -3-hydroxyacyl)- N -acetylglucosamine deacetylase LpxC is an essential enzyme in the biosynthesis of lipid A, the outer membrane anchor of lipopolysaccharide and lipooligosaccharide in Gram-negative bacteria. The development of LpxC-targeting antibiotics toward clinical therapeutics has been hindered by the limited antibiotic profile of reported non-hydroxamate inhibitors and unexpected cardiovascular toxicity observed in certain hydroxamate and non–hydroxamate-based inhibitors. Here, we report the preclinical characterization of a slow, tight-binding LpxC inhibitor, LPC-233, with low picomolar affinity. The compound is a rapid bactericidal antibiotic, unaffected by established resistance mechanisms to commercial antibiotics, and displays outstanding activity against a wide range of Gram-negative clinical isolates in vitro. It is orally bioavailable and efficiently eliminates infections caused by susceptible and multidrug-resistant Gram-negative bacterial pathogens in murine soft tissue, sepsis, and urinary tract infection models. It displays exceptional in vitro and in vivo safety profiles, with no detectable adverse cardiovascular toxicity in dogs at 100 milligrams per kilogram. These results establish the feasibility of developing oral LpxC-targeting antibiotics for clinical applications.

20 September 2018 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
ATArtak Tovmasyan
Artak Tovmasyan
JBJacqueline C. Bueno-Janice
Jacqueline C. Bueno-Janice
MJMelba C. Jaramillo
Melba C. Jaramillo
RSRomulo S. Sampaio
Romulo S. Sampaio
JRJulio Reboucas
Julio Reboucas
Ines Batinic-HaberleInes Batinic-Haberle
Ines Batinic-Haberle
Aims: We aim here to demonstrate that radiation (RT) enhances tumor sensitization by only those Mn complexes that are redox active and cycle with ascorbate (Asc), thereby producing H 2 O 2 and utilizing it subsequently in protein S -glutathionylation in a glutathione peroxidase (GPx)-like manner. In turn, such compounds affect cellular redox environment, described by glutathione disulfide (GSSG)/glutathione (GSH) ratio, and tumor growth. To achieve our goal, we tested several Mn complexes of different chemical and physical properties in cellular and animal flank models of 4T1 breast cancer cell. Four other cancer cell lines were used to substantiate key findings. Results: Joint administration of cationic Mn porphyrin (MnP)-based redox active compounds, MnTE-2-PyP 5+ or MnTnBuOE-2-PyP 5+ with RT and Asc contributes to high H 2 O 2 production in cancer cells and tumor, which along with high MnP accumulation in cancer cells and tumor induces the largest suppression of cell viability and tumor growth, while increasing GSSG/GSH ratio and levels of total S -glutathionylated proteins. Redox-inert MnP, MnTBAP 3− and two other different types of redox-active Mn complexes (EUK-8 and M40403) were neither efficacious in the cellular nor in the animal model. Such outcome is in accordance with their inability to catalyze Asc oxidation and mimic GPx. Innovation: We provided here the first evidence how structure-activity relationship between the catalytic potency and the redox properties of Mn complexes controls their ability to impact cellular redox environment and thus enhance the radiation and ascorbate-mediated tumor suppression. Conclusions: The interplay between the accumulation of cationic MnPs and their potency as catalysts for oxidation of Asc, protein cysteines, and GSH controls the magnitude of their anticancer therapeutic effects.